
Coronavirus / COVID
Latest News


House Lawmakers Probe FDA Over COVID-19 Vaccine Death Claims and Proposed Vaccine Regulation Changes
Latest Videos

More News

A review of vaccine safety and effectiveness conducted by the Vaccine Integrity Project, independent of the CDC's ACIP, reflects its stated purpose as "dedicated to safeguarding vaccine use in the US."

Seven months of clinical data corroborated emergency authorization of 2024-2025 mRNA COVID-19 vaccines for circulating JN.1 subvariants.

Dynavax and Vaxart have entered into a license and collaboration agreement to advance Vaxart’s investigational oral COVID-19 vaccine, with phase 2b data expected in late 2026.

George Sakoulas, MD, discusses how transitioning pneumonia patients from IV to oral therapy after 3 to 4 days of clinical stability supports effective 7-day treatment courses, while patients who are immunocompromised and those with Pseudomonas infections require individualized, extended management.

George Sakoulas, MD, discusses how updated guidelines recommend shorter antibiotic courses (5 to 7 days) for patients with pneumonia, emphasizing that early aggressive treatment within the first 72 hours is crucial for reducing hospital stays and improving patient outcomes.

FDA clearance paves the way for Invivyd to launch 2 phase 3 trials of VYD2311, a monoclonal antibody designed as a safe, convenient, vaccine alternative for COVID-19 prevention.

George Sakoulas, MD, discusses how ceftaroline serves as an effective stewardship-aligned option for community-acquired pneumonia involving gram-positive organisms, particularly in older and high-risk patients, while noting its limitations in gram-negative and health care–associated infections.

The center’s chief scientific officer David Perlin, PhD, provides some insights on the evolution of its antiviral program from its foundation in treating COVID-19 to addressing all pan-coronaviruses.

George Sakoulas, MD, discusses how antimicrobial selection for patients with pneumonia depends on illness severity, seasonal pathogen patterns, comorbidities, and prior antibiotic exposure, with particular attention to high-risk populations requiring tailored therapy.

William Schaffner, MD, provides more context to the committee’s vaccines recommendations.

George Sakoulas, MD, discusses how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, while declining vaccine uptake among younger populations threatens to leave vulnerable groups increasingly exposed to seasonal illness complications.

Georges C.Benjamin, MD, executive director of the American Public Health Association, details practical implications for clinical teams.

Insights from Jaya Aysola, MD, MPH, DTMH; and John C. Lin, MD candidate, on clinical workflows, social needs screening, and policy levers.

Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.

William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.

Azelastine Nasal Spray Reduces SARS-CoV-2 Infections in Phase 2 Trial
Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.

Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.

FDA Approves Moderna’s Updated COVID-19 Vaccines Targeting LP.8.1 Variant for Fall 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.

FDA Approves Updated COVID-19 Vaccines for Fall 2025, Restricts Eligibility to High-Risk Groups
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.

New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.

STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.












































































































